Antares Pharma, Inc. (NASDAQ:ATRS) dropped 2.8% on Monday . The company traded as low as $1.71 and last traded at $1.84. Approximately 1,034,100 shares were traded during trading, a decline of 35% from the average daily volume of 1,585,472 shares. The stock had previously closed at $1.79.

ATRS has been the topic of a number of recent research reports. Vetr raised Antares Pharma from a “hold” rating to a “buy” rating and set a $3.42 target price on the stock in a research report on Tuesday, July 18th. HC Wainwright set a $5.00 target price on Antares Pharma and gave the stock a “buy” rating in a research report on Friday, October 13th. Piper Jaffray Companies reissued a “buy” rating on shares of Antares Pharma in a research report on Friday, September 8th. Finally, ValuEngine downgraded Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $3.84.

The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.01 million. Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The firm’s revenue was up 11.9% compared to the same quarter last year. research analysts anticipate that Antares Pharma, Inc. will post -0.11 EPS for the current fiscal year.

In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Leonard S. Jacob sold 230,000 shares of Antares Pharma stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATRS. Bank of New York Mellon Corp boosted its holdings in Antares Pharma by 20.1% during the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock valued at $476,000 after purchasing an additional 28,029 shares in the last quarter. California Public Employees Retirement System boosted its holdings in Antares Pharma by 14.4% during the first quarter. California Public Employees Retirement System now owns 934,300 shares of the specialty pharmaceutical company’s stock valued at $2,653,000 after purchasing an additional 117,300 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Antares Pharma by 4.3% during the first quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock valued at $15,958,000 after purchasing an additional 232,349 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Antares Pharma by 4.8% during the first quarter. Geode Capital Management LLC now owns 958,234 shares of the specialty pharmaceutical company’s stock valued at $2,721,000 after purchasing an additional 43,629 shares in the last quarter. Finally, Morgan Stanley boosted its holdings in Antares Pharma by 153.3% during the first quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock valued at $2,829,000 after purchasing an additional 602,834 shares in the last quarter. 36.84% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/antares-pharma-inc-atrs-trading-down-2-8/1705848.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.